Keen Eye, a technology company based in Paris, has partnered with Iris Pharma, a contract research organization (CRO) dedicated to ophthalmology, to bring artificial intelligence (AI) in ophthalmology studies.
Image: Keen Eye partners with Iris Pharma. Photo: Courtesy of Markus Spiske/Unsplash.
The partnership intends to offer Iris Pharma AI applications to make assays faster, more reliable and more efficient.
Keen Eye’s advanced AI technology allows Iris Pharma to optimize the performance of bioimaging analysis during preclinical ophthalmic drug development and in the future for clinical development.
Iris Pharma President Yann Quentric said: “Their solution is faster than classical methods, robust and reliable, erasing inter-individual variability, improving Iris Pharma and its customers ability to develop ocular innovative products.”
Keen Eye founder and CEO Sylvain Berlemont said: “We are very happy to team up and bring our expertise in computer vision to Iris Pharma. Through this partnership, we are expecting to contribute to the most challenging image-based assays to better fight eye diseases.”
Established in 2013, Keen Eye is focused on bringing AI for the life sciences industry to benefit biologists, pathologists and patients.
Keen Eye is building decision-support and good laboratory practice (GLP)-compliant image analysis solutions to accelerate the development of new therapies with better, faster and accurate analytics.
The French firm is also developing web-based solutions which can help biologists and pathologists, who spend thousands of hours on microscope. It offers image quantification applications that use deep learning technology.
Iris Pharma company supports clients around the world in navigating every stage of drug and medical development process including in vivo ocular efficacy studies, good laboratory practice (GLP) preclinical studies, bioanalysis, clinical trials, and marketing surveys.
The company has helped in the development of nearly 70 ocular drugs and medical devices to market in the past 28 years, by partnering with its clients. It also offers consulting services to help clients to determine the best indication for molecules and products in development.